The Outcome and Safety of Re-challenge Lutetium-177 PSMA (<sup>177</sup>Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report.

Maharaj, Masha; Heslop, Lucille; Govender, Trisha; Korowlay, Nisaar; Singh, Aviral; Choudhary, Partha; Sathekge, Mike

The Outcome and Safety of Re-challenge Lutetium-177 PSMA (¹⁷⁷Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report.

Maharaj, Masha; Heslop, Lucille; Govender, Trisha; Korowlay, Nisaar; Singh, Aviral; Choudhary, Partha; Sathekge, Mike.

Affiliation

Maharaj M; Department of Nuclear Medicine, Imaging and Therapy Centres of Excellence, Durban, KwaZulu Natal South Africa.
Heslop L; Durban Oncology Centre, West Ridge, Durban, South Africa.
Govender T; Department of Nuclear Medicine, Imaging and Therapy Centres of Excellence, Durban, KwaZulu Natal South Africa.
Korowlay N; Division of Nuclear Medicine, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa.
Singh A; Theranostics Center for Molecular Radiotherapy and Molecular Imaging (PET/CT) ENETS Center of Excellence, Zentralklinik Bad Berka GmbH, Bad Berka, Germany.
Choudhary P; Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Sathekge M; Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa.

Nucl Med Mol Imaging ; 55(3): 136-140, 2021 Jun.

Article de En | MEDLINE | ID: mdl-34093893

Mots clés

177Lu; Docetaxel; PSMA; Prostate cancer; Radiosensitizer; Re-challenge

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Nucl Med Mol Imaging Année: 2021 Type de document: Article